Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease

O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea)

Source: International Congress 2018 – Challenges in treating tuberculosis and nontuberculous mycobacteria
Session: Challenges in treating tuberculosis and nontuberculous mycobacteria
Session type: Poster Discussion
Number: 538
Disease area: Respiratory infections

Congress or journal article abstractWebcastSlide presentation

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
O. Kim (Seoul, Republic of Korea), B. Kwon (Seoul, Republic of Korea), Y. Koh (Seoul, Republic of Korea), W. Kim (Seoul, Republic of Korea), J. Song (Seoul, Republic of Korea), Y. Oh (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), S. Lee (Seoul, Republic of Korea), J. Lee (Seoul, Republic of Korea), C. Lim (Seoul, Republic of Korea), C. Choi (Seoul, Republic of Korea), J. Huh (Seoul, Republic of Korea), S. Hong (Seoul, Republic of Korea), T. Shim (Seoul, Republic of Korea), K. Jo (Seoul, Republic of Korea). Association between injectable aminoglycoside treatment duration and outcomes in cavitary Mycobacterium avium complex lung disease. 538

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Paradoxical response during antibiotic treatment in patients with Mycobacterium avium complex lung disease
Source: Virtual Congress 2020 – Non-tuberculous mycobacterial infections and bronchiectasis
Year: 2020


Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease
Source: Eur Respir J, 54 (1) 1900118; 10.1183/13993003.00118-2019
Year: 2019



Clinical efficacy and safety of fluoroquinolone containing regimens in patients with Mycobacterium avium complex pulmonary disease
Source: Eur Respir J, 55 (4) 1901240; 10.1183/13993003.01240-2019
Year: 2020



The effect of combined chemotherapy according to the guidelines on the treatment for Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2002; 20: Suppl. 38, 546s
Year: 2002

Combined chemotherapy in Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2005; 26: Suppl. 49, 657s
Year: 2005

Outcomes of Mycobacterium avium complex lung disease based on clinical phenotype
Source: Eur Respir J, 50 (3) 1602503; 10.1183/13993003.02503-2016
Year: 2017



Factors related to response to intermittent treatment of mycobacterium avium complex lung disease
Source: Eur Respir J 2006; 28: Suppl. 50, 557s
Year: 2006

Long-term observation of pulmonary Mycobacterium avium complex disease treated with chemotherapy following the guidelines for treatment
Source: Annual Congress 2009 - Extrapulmonary tuberculosis and non-tuberculous-mycobacteria (NTM) infections
Year: 2009


Sentinel-site surveillance of Mycobacterium avium complex pulmonary disease
Source: Eur Respir J 2005; 26: 1092-1096
Year: 2005



Management of Mycobacterium avium complex and Mycobacterium abscessus pulmonary disease: therapeutic advances and emerging treatments
Source: Eur Respir Rev, 31 (163) 210212; 10.1183/16000617.0212-2021
Year: 2022



Comparison of safety and efficacy between clarithromycin- and azithromycin-containing regimens in Mycobacterium avium complex lung disease
Source: International Congress 2019 – Complex respiratory infections in clinical practice
Year: 2019

Inhaled therapies, azithromycin and Mycobacterium abscessus in cystic fibrosis patients
Source: Eur Respir J 2013; 41: 1101-1106
Year: 2013



The new “Hesitation Blues”: initiating Mycobacterium avium complex lung disease therapy
Source: Eur Respir J , 49 (3) 1700110; DOI: 10.1183/13993003.00110-2017
Year: 2017


Hospital-based antibiotic use in patients with Mycobacterium avium complex
Source: ERJ Open Res, 4 (4) 00109-2018; 10.1183/23120541.00109-2018
Year: 2018



Long-term relapses after 12-month treatment for Mycobacterium kansasii lung disease
Source: Eur Respir J 2009; 33: 148-152
Year: 2009



The impact of different antibiotic treatment regimens on mortality in Mycobacterium avium complex pulmonary disease: a population-based cohort study
Source: Eur Respir J, 56 (3) 1901875; 10.1183/13993003.01875-2019
Year: 2020



Clinical features of pulmonary Mycobacterium avium intracellulare complex disease with a solitary pulmonary nodule in Japan
Source: Eur Respir J 2005; 26: Suppl. 49, 687s
Year: 2005

Clinical characteristics and treatment outcomes of patients with macrolide-resistant Mycobacterium avium complex pulmonary disease: a systemic review and meta-analysis
Source: International Congress 2019 – Clinical investigations of non-TB mycobacterial infection
Year: 2019


Clinical analysis of pulmonary Mycobacterium avium complex disease in Japan
Source: Annual Congress 2012 - Non-tuberculous and tuberculous mycobacterial infections: from epidemiology to clinical findings
Year: 2012

Natural history of Mycobacterium avium complex lung disease in untreated patients with stable course
Source: Eur Respir J , 49 (3) 1600537; DOI: 10.1183/13993003.00537-2016
Year: 2017